Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Acceptability of fluzone intradermal vaccine to patients and vaccine administrators.

Foy JE, Hendriksz T, Malouf P, Tobin A.

J Am Osteopath Assoc. 2013 Feb;113(2):134-43.

PMID:
23412675
2.

Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.

Dhont PA, Albert A, Brenders P, Podwapinska A, Pollet A, Scheveneels D, Tihon F, Verheyden I, Victor J, Samson SI.

Adv Ther. 2012 Jun;29(6):562-77. doi: 10.1007/s12325-012-0025-9. Epub 2012 Jun 1.

PMID:
22678831
3.

Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.

Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.

Vaccine. 2014 May 1;32(21):2507-17. doi: 10.1016/j.vaccine.2013.09.074. Epub 2013 Oct 11.

4.

Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults.

Ansaldi F, de Florentiis D, Durando P, Icardi G.

Expert Rev Vaccines. 2012 Jan;11(1):17-25. doi: 10.1586/erv.11.154. Review.

PMID:
22149703
5.

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH.

Vaccine. 2013 Dec 5;31(50):6034-40. doi: 10.1016/j.vaccine.2013.09.012. Epub 2013 Sep 20.

PMID:
24055306
6.

Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study.

Durando P, Alicino C, Alberti M, Sticchi L, Turello V, Marensi L, Caiazzo AL, Panico MG, Giugliano F, Parlato A, Peluso F, Sgricia S, Icardi G; Italian Intradermal Influenza Vaccine Working Group.

Adv Ther. 2012 Apr;29(4):312-26. doi: 10.1007/s12325-012-0012-1. Epub 2012 Apr 13.

PMID:
22529024
7.

Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina.

Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F.

Adv Ther. 2011 Aug;28(8):640-9. doi: 10.1007/s12325-011-0042-0. Epub 2011 Jul 11.

PMID:
21751080
8.

Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.

Chi RC, Rock MT, Neuzil KM.

Clin Infect Dis. 2010 May 15;50(10):1331-8. doi: 10.1086/652144.

PMID:
20377407
9.

Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey.

Prymula R, Usluer G, Altinel S, Sichova R, Weber F.

Adv Ther. 2012 Jan;29(1):41-52. doi: 10.1007/s12325-011-0090-5. Epub 2012 Jan 3.

PMID:
22228256
10.

Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.

Leung MK, You JH.

Vaccine. 2016 May 11;34(22):2469-76. doi: 10.1016/j.vaccine.2016.04.008. Epub 2016 Apr 11.

PMID:
27079928
11.

Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.

Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY.

Vaccine. 2012 Oct 5;30(45):6427-35. doi: 10.1016/j.vaccine.2012.08.014. Epub 2012 Aug 18.

PMID:
22910287
12.

A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine.

Coleman BL, McGeer AJ, Halperin SA, Langley JM, Shamout Y, Taddio A, Shah V, McNeil SA.

Vaccine. 2012 Sep 28;30(44):6287-93. doi: 10.1016/j.vaccine.2012.08.006. Epub 2012 Aug 16.

PMID:
22902784
13.

Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials.

Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH.

Hum Vaccin. 2010 Apr;6(4):336-45. Epub 2010 Apr 26.

PMID:
20372083
14.

Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.

Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K.

Vaccine. 2013 Oct 9;31(43):4984-7. doi: 10.1016/j.vaccine.2013.08.001. Epub 2013 Aug 29.

PMID:
23994022
15.

A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events.

Marra F, Young F, Richardson K, Marra CA.

Influenza Other Respir Viruses. 2013 Jul;7(4):584-603. doi: 10.1111/irv.12000. Epub 2012 Sep 13. Review.

16.

Dose sparing with intradermal injection of influenza vaccine.

Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.

N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub 2004 Nov 3.

17.

The immunogenicity of intradermal influenza vaccination in COPD patients.

Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra KN.

Vaccine. 2010 May 28;28(24):4045-51. doi: 10.1016/j.vaccine.2010.04.006. Epub 2010 Apr 20.

PMID:
20412877
18.
19.

Antibody responses after dose-sparing intradermal influenza vaccination.

Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P.

Vaccine. 2007 Jan 8;25(4):659-63. Epub 2006 Sep 1.

PMID:
17011678
20.

Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers.

Coleman BL, McNeil SA, Langley JM, Halperin SA, McGeer AJ.

Vaccine. 2015 Nov 27;33(48):6635-40. doi: 10.1016/j.vaccine.2015.10.095. Epub 2015 Oct 31.

PMID:
26529074

Supplemental Content

Support Center